Active	Status	Sponsor type	Region	Phase	Filter
4 Active 2 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
MOYAL, Elizabeth
POLO, NCT04702581: A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery	Recruiting	3	280	Europe	PCV chemotherapy, Radiotherapy and PCV chemotherapy	Hospices Civils de Lyon	Oligodendroglioma, Low-grade Oligodendroglioma, 1p19q Codeletion	12/30	12/30
CLINGLIO, NCT04250922 / 2018-000365-37: LAM561 With RT and TMZ for Adults With Glioblastoma	Active, not recruiting	2/3	140	Europe, RoW	LAM561, TMZ, RT	Laminar Pharmaceuticals, Laboratory Corporation of America, Northern Institute for Cancer Research, Newcastle, Theradis pharma, LIPODOM THERAPEUTICS	Primary Glioblastoma, Glioblastoma Multiforme	10/24	05/25
STERIMGLI, NCT02866747 / 2016-001614-16: A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma	Completed	1/2	108	Europe	Hypofractionated stereotactic radiation therapy, Durvalumab	Institut Claudius Regaud, AstraZeneca	Glioblastoma	11/24	11/24
EXOFIELDS, NCT06222138: Study of Biologic Tumor and Plasma Biomarkers of Response to TTFields in Patients Treated for Newly Diagnosed Glioblastoma	Recruiting	N/A	80	Europe	The samples described below will be collected:	Institut Claudius Regaud, NovoCure Ltd.	Glioblastoma	10/27	10/27